Chief Medical Officer, Professor Chris Baggoley

I understand that this has been, and will continue to be, a difficult time for many women who have PIP breast implants. Some women may be worried about their implants and the harm that they may cause, and they may still have unanswered questions.

This report aims to present the information we have at the moment, to provide answers to common questions and to assist women who have to make choices about their own PIP breast implants.

So far, scientific tests have identified some differences between the PIP breast implants and other brands of silicone breast implants, but these differences are small and do not indicate that there is an increased safety risk associated with PIP implants.

I have talked to a variety of experts about what these test results mean. In particular, I would like to thank the members of the Chief Medical Officer’s Clinical Advisory Committee, who have helped me understand what these tests mean for both clinicians and consumers.

As the Therapeutic Goods Administration and international bodies continue to accumulate evidence as part of their ongoing activities, we expect there will be more information to review. Where the information is different from that already known I would like to reassure you that we will discuss it with experts and provide updated public advice.